Feasibility study of the Selinexor-Melphalan combined conditioning regimen for autologous stem cell transplan-tation in multiple myeloma
SU Shuai
XU Bin
TONG Xi-wen
ZHU Yi
WEN Zhuo-xin
MAO Xia
WANG Di
LI Chun-rui
ZHANG Dong-hua
Abstract：Objective To explore the feasibility of the Selinexor-Melphalan combined conditioning regimen for autologous stem cell transplantation in multiple myeloma.Methods From April 2023 to June 2024,11 patients diagnosed with MM who underwent ASCT enrolled in Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology.The conditioning regimen included Selinexor 60 mg on days-10 and-3 prior to hematopoietic stem cell infusion and a standard or reduced dose of Melphalan on days-2 before infusion.The primary endpoints were the complete response(CR)rate and safety,while secondary endpoints included progression-free survival(PFS),measurable residual disease(MRD)negativity rate,overall survival(OS),and improvement in renal function.Results The median time of neutrophil and platelet engraftment was 13(12-13)d and 15(12-16)d,respectively.Of the 11 patients,Nine patients achieved CR one month after ASCT,while two were still PR.One patient experienced disease progression three months post-ASCT,with a CR rate and MRD-negative rate of 72.7％three months after transplantation.Treatment-related adverse events included hyponatremia(90.9％),nausea(81.8％),vomiting(54.5％),hypokalemia(45.5％),febrile neutropenia(45.5％),oral mucositis(45.5％),and pneumonia(9.1％).All patients were alive at the end of the follow-up,with median PFS and OS not yet reached.Conclusion The Selinexor-Melphalan combined conditioning regimen for MM patients undergoing ASCT is feasible and tolerable.
Keywords：multiple myelomaautologous stem cell transplantationconditioning regimenSelinexorMelphalan
Publication Date：2025-01-31
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 73-77,88 )